The Swinging Pendulum in Treatment for Hypothyroidism: From (and Toward?) Combination Therapy
Open Access
- 9 July 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 10, 446
Abstract
Thyroid hormone replacement for hypothyroidism can be achieved via several approaches utilizing different preparations of thyroid hormones, T3, and/or T4. “Combination therapy” involves administration of both T3 and T4, and was technically the first treatment for hypothyroidism. It was lauded as a cure for the morbidity and mortality associated with myxedema, the most severe presentation of overt hypothyroidism. In the late nineteenth and the early Twentieth centuries, combination therapy per se could consist of thyroid gland transplant, or more commonly, consumption of desiccated animal thyroid, thyroid extract, or thyroglobulin. Combination therapy remained the mainstay of therapy for decades despite development of synthetic formulations of T4 and T3, because it was efficacious and cost effective. However, concerns emerged about the consistency and potency of desiccated thyroid hormone after cases were reported detailing either continued hypothyroidism or iatrogenic thyrotoxicosis. Development of the TSH radioimmunoassay and discovery of conversion of T4-to-T3 in humans led to a major transition in clinical practices away from combination therapy, to adoption of levothyroxine “monotherapy” as the standard of care. Levothyroxine monotherapy has a favorable safety profile and can effectively normalize the serum TSH, the most sensitive marker of hypothyroidism. Whether levothyroxine monotherapy restores thyroid hormone signaling within all tissues remains controversial. Evidence of persistent signs and symptoms of hypothyroidism during levothyroxine monotherapy at doses that normalize serum TSH is mounting. Hence, in the last decade there has been acknowledgment by all thyroid professional societies that there may be a role for the use of combination therapy; this represents a significant shift in the clinical practice guidelines. Further bolstering this trend are the recent findings that the Thr92AlaD2 polymorphism may reduce thyroid hormone signaling, resulting in localized and systemic hypothyroidism. This strengthens the hypothesis that treatment options could be personalized, taking into consideration genotypes and comorbidities. The development of long-acting formulations of liothyronine and continued advancements in development of thyroid regenerative therapy, may propel the field closer to adoption of a physiologic thyroid hormone replacement regimen with combination therapy.Keywords
This publication has 123 references indexed in Scilit:
- Thyroid Follicle Formation and Thyroglobulin Expression in Multipotent Endodermal Stem CellsThyroid®, 2013
- Generation of functional thyroid from embryonic stem cellsNature, 2012
- Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic PatientsPLOS ONE, 2011
- Hypothyroidism and Thyroid Substitution: Historical AspectsJournal of Thyroid Research, 2011
- TSH may not be a good marker for adequate thyroid hormone replacement therapyWiener klinische Wochenschrift, 2005
- Thyroxine replacement therapy and circulating lipid concentrationsClinical Endocrinology, 1993
- A New Radioimmunoassay for Plasma l-Triiodothyronine: Measurements in Thyroid Disease and in Patients Maintained on Hormonal ReplacementJournal of Clinical Investigation, 1972
- Inhibition of thyrotropin response to thyrotropin-releasing hormone by small quantities of thyroid hormonesJournal of Clinical Investigation, 1972
- Triiodothyronine RadioimmunoassayJournal of Clinical Investigation, 1972
- Note on the Treatment of Myx dema by Hypodermic Injections of an Extract of the Thyroid Gland of a SheepBMJ, 1891